EURICE Expands its Health Innovation Ecosystem with Seven New Projects
Health research is entering a new era, one that goes beyond treatment to focus on prevention, early detection and empowering people to take control of their health. From chronic diseases to cancer, and from global pandemics to AI-driven breakthroughs, innovation is moving fast and at EURICE we are excited to be a part of it.
In the first months of 2025, we have kicked off seven bold new researcundh initiatives expanding our Health Innovation Ecosystem aimed at some of Europe’s most urgent health challenges. These international collaborations combine cutting-edge science, human insight and digital technologies to reimagine the future of healthcare.
“People-centred health research can be a game changer,” says Dr Sanja Šale, Senior Innovation Manager at EURICE. “By integrating early detection, prevention and AI, these seven new projects mark a significant step forward in how we collaborate internationally and address Europe’s most urgent health challenges.”
Our newest projects explore:
- Imaging biomarkers to detect arthritis before symptoms worsen
- Pandemic preparedness using insights from the Marburg virus as well as developing a novel antiviral drug
- Biomarkers for early detection of Crohn’s disease and other inflammatory bowel diseases
- AI-powered data chips for better musculoskeletal disease management
- Revolutionary cancer research using light and immunotherapy to eliminate tumour cells with precision
Each project reflects EURICE’s commitment and passion to work hand in hand with our partners within the European Union’s research framework to find solutions to improve people’s lives, break barriers in innovative research and pioneer new ground.
Discover more about our newest projects and collaborations:
AutoPiX: Advancing Imaging for Arthritis Care
AutoPiX is revolutionising arthritis treatment by integrating advanced imaging biomarkers with AI technologies. Focusing on rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis, this project aims to enhance diagnosis, monitoring and personalised care, ultimately improving outcomes for patients with rheumatic and musculoskeletal diseases.
COMBINE: Strengthening Pandemic Preparedness
COMBINE utilises the Marburg virus as a model to deepen our understanding of virus-cell interactions. By identifying key factors in viral entry, the project seeks to develop innovative strategies for antiviral drug and vaccine development, bolstering our readiness against future viral outbreaks.
INTERCEPT: Pioneering a future without Crohn’s disease
INTERCEPT is conducting Europe's first ever trial to prevent Crohn’s Disease before symptom onset. By validating biomarkers and developing a blood-based risk score, the project aims to identify high-risk individuals and implement early interventions, potentially transforming disease management and prevention strategies making diagnosis earlier than early.
NoVir: A New Step Toward Better Protection Against Future Pandemics
Building upon the success of mRNA vaccine technology, NoVir will conduct several preclinical and clinical studies to evaluate the potential of ETH47, a first-in-class mRNA-based antiviral therapy, to offer a paradigm shift in the treatment and prevention of respiratory and broader systemic infections. NoVir will advance ETH47’s clinical development and explore its wider applications beyond respiratory conditions to address additional critical unmet needs in high-risk populations.
PerPrev-CID: Personalising Prevention in Chronic Inflammatory Diseases
PerPrev-CID focuses on early detection and prevention of rheumatoid arthritis and inflammatory bowel disease. By leveraging molecular diagnostics, digital health tools and patient-centred approaches, the project aims to predict disease progression and implement timely interventions, enhancing patient outcomes.
SCALPEL: Light Meets Precision with A Click
SCALPEL is pioneering a breakthrough approach to cancer therapy combining the precision of light-based technology with the power of immunotherapy. The innovative method uses light-activated click chemistry to tag and destroy cancer cells with exceptional accuracy, while helping the body prevent future recurrence.
SmILE: Innovating Musculoskeletal Health Monitoring
SmILE is developing AI-driven data chips to monitor musculoskeletal non-communicable diseases. By enabling real-time tracking of disease progression, the project seeks to enhance early detection, personalise treatment plans and improve quality of life for patients.
